Skip to main content
Industry News
AbbVie reportedly drops global patent rights for HIV drug
3/24/2020

AbbVie will reportedly give up global patent rights for its HIV drug Kaletra, which is being evaluated in several clinical trials as treatment for severe COVID-19, to address rising demand for experimental coronavirus drugs. The move will allow countries to buy Kaletra generics if the drug is found to be an effective COVID-19 treatment or if a shortage occurs.

Full Story: